CMN-005 by CoImmune for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

AI models using retinal images achieve perfect accuracy in diagnosing autism

Study demonstrates that deep ensemble models (DEMs) using high-resolution retinal images can accurately diagnose autism spectrum disorder (ASD) in children, achieving an AUROC of 1.00

December 19, 2023

New mobile app aims to bridge the gap in communication for people with ASD

Researchers from the Universitat Oberta de Catalunya (UOC) and Parc Taulí University Hospital have developed a mobile application that compiles and presents valuable pieces of

July 13, 2023

J&J allows generic production for TB drug following public dissent – Pharmaceutical Technology

Johnson and Johnson sign at an American multinational corporation office. Credit: Michael Vi via Shutterstock. Following a public call out from a popular young adult

July 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.